Total (n=188) | |
Age, years: median (range) | 59 (19–89) |
Male, number (%) | 95 (51) |
Race, number (%) | |
White | 168 (89.4) |
Asian | 13 (6.9) |
Hispanic | 3 (1.6) |
Black | 1 (0.5) |
Other | 3 (1.6) |
Disease duration, years: median (range) | 5.0 (0.4–34.5) |
Prior treatment with cyclophosphamide | |
Number of patients (%) | 149 (79.3) |
Cumulative dose, grams (g): median (range) | 9 (0.15–301) |
Prior rituximab therapy | |
Number of patients (%) | 67 (35.6) |
Cumulative dose, grams (g): median (range) | 3910 (1000–16000) |
Glucocorticoid induction regimen, number (%) | |
1 mg/kg/day starting dose (1A) | 54 (28.7) |
0.5 mg/kg/day starting dose (1B) | 134 (71.3) |
ANCA type, number (%) | |
Antiproteinase 3 | 137 (72.9) |
Antimyeloperoxidase | 51 (27.1) |
Relapse type on entry into trial, number (%) | |
Severe | 119 (63.3) |
Non-severe | 69 (36.7) |
BVAS/WG: median (range) | 5 (3–14) |
ANCA, antineutrophil cytoplasmic antibody; BVAS/WG, Birmingham Vasculitis Activity Score for Wegener's granulomatosis.